Pages
Products

Humanized Fc Mice: FcRn & FcγR Evaluation

Overview FcRn Models FcγR Models Applications Characterization FAQ

Humanized Fc receptor models for in vivo PK, effector-function, and pharmacological evaluation of Fc-dependent therapeutics

Fc-dependent pharmacology can introduce an additional species barrier beyond the therapeutic target itself. We provide hFcRn and hFcγR humanized mouse models to evaluate Fc-dependent PK, half-life, immune effector activity, and pharmacological responses of AOCs, Fc-containing CGT constructs, and other Fc-dependent therapeutics.

hFcRn micehFcγR miceFc-dependent PKFc-mediated effector functionAOC pharmacology

Why Does Fc Humanization Matter?

Human and mouse Fc receptor pathways differ in receptor binding, recycling efficiency and immune effector functions. These species differences may affect the interpretation of PK, half-life and Fc-mediated pharmacological responses.

Conventional Mice vs. Humanized Fc Mice

Conventional Mice

  • Mouse FcRn interactions may not reflect human IgG recycling and persistence.
  • Mouse FcγR binding profiles differ from human FcγR interactions.
  • Fc-mediated ADCC and ADCP may differ from human immune responses.
  • Fc engineering effects may not translate directly to human pharmacology.

Humanized Fc Mice

  • Human FcRn supports more human-relevant IgG recycling and PK evaluation.
  • Human FcγR enables evaluation of human-specific Fc-receptor interactions.
  • Supports assessment of human FcγR-dependent effector functions.
  • Facilitates comparative evaluation of Fc-engineered variants in a humanized receptor context.

Key Takeaway: Fc humanization complements target humanization by addressing species differences in Fc-dependent PK and immune effector mechanisms, providing a more relevant basis for in vivo pharmacological evaluation.

Where FcRn and FcγR Humanization Fit in Your Model Strategy

Humanization Component Main Question Addressed Typical Application
Target humanization Can the molecule recognize the human antigen, receptor, or RNA sequence? Human-specific siRNA, ASO, AOC payloads, human antigen-targeted biologics
Delivery receptor humanization Can the therapeutic bind the intended human receptor for tissue or cell uptake? TfR1-targeted AOCs and receptor-mediated delivery platforms
• hFcRn humanization Does FcRn interaction affect half-life, clearance, exposure, or dosing interval? Fc-engineered antibodies, AOCs, antibody-siRNA conjugates
• hFcγR humanization Can FcγR interactions affect immune-cell engagement, uptake, depletion, or Fc-mediated activity? Fc-engineered antibodies, T-cell engagers, selected Fc-containing modalities
Immune-system humanization Is a human immune-cell context required for persistence, activation, or cytokine evaluation? CAR-T, TCE, and immuno-oncology studies

Fc humanization does not replace target humanization. It addresses Fc-dependent PK or Fc-mediated biology, while target, receptor, immune-system, and disease-model components address other parts of the pharmacological mechanism.

hFcRn Humanized Mice for PK Evaluation

FcRn-mediated recycling can substantially influence the systemic persistence of IgG- and Fc-containing therapeutics. hFcRn humanized models provide a more human-relevant background for evaluating Fc-dependent exposure and half-life.

Key Applications

  • PK profiling of Fc-containing therapeutics
  • Comparison of Fc-engineered variants
  • Half-life extension strategies
  • Exposure-response assessment
  • Evaluation of Fc-containing AOCs and related constructs

Key Readouts

Serum Concentration→AUC / Cmax→t½ / Clearance→Exposure-Response

Where required, hFcRn models can be combined with immunodeficient backgrounds to reduce confounding from anti-drug antibody responses during PK studies.

hFcγR Humanized Mice for Effector-Function Evaluation

FcγR-mediated interactions can influence the activity of antibodies and other Fc-containing therapeutics through immune effector cells. Human FcγR models provide an in vivo system for evaluating Fc-dependent cellular responses when these mechanisms are relevant to the therapeutic MOA.

Key Applications

  • FcγR interaction and functional ranking
  • ADCC evaluation
  • ADCP evaluation
  • Target-cell depletion
  • Comparison of Fc-active and Fc-silenced variants
  • Fc engineering for altered effector function

Key Readouts

FcγR Engagement→Immune-Cell Interaction→Depletion / ADCC / ADCP→Downstream Response

The specific readouts are selected according to the Fc format and intended mechanism rather than applied as a fixed assay panel.

Applications in Oligonucleotide and CGT Pharmacology

Antibody-Oligonucleotide Conjugates (AOCs)

Human FcRn models support the evaluation of Fc-dependent systemic exposure and antibody recycling, while integration with humanized target or delivery-receptor models enables assessment of tissue oligonucleotide delivery and target RNA knockdown.

Fc-Containing CGT Constructs

For cell and gene therapy constructs incorporating Fc domains, humanized Fc models support the assessment of Fc-dependent pharmacokinetics and, where relevant, interactions with FcγR-expressing immune cells.

Fc-Engineered Therapeutics

Humanized FcRn and/or FcγR models enable comparative evaluation of Fc-engineered variants, including modifications designed to alter serum persistence, receptor binding, or immune effector activity.

Combination with Target or Delivery-Receptor Humanization

Combining Fc humanization with target or delivery-receptor humanization helps address multiple species-specific barriers within one study, linking systemic exposure and Fc-dependent activity with target engagement and downstream pharmacodynamic responses.

Model Characterization and Pharmacological Relevance

Characterization is designed around the specific Fc pathway and therapeutic mechanism.

Molecular Characterization

  • Human FcRn or FcγR expression
  • Tissue and immune-cell distribution
  • Expression consistency

Functional Characterization

  • Human IgG/Fc-FcRn interaction
  • Fc-FcγR binding
  • Relevant Fc-dependent cellular responses

Pharmacological Characterization

  • PK and half-life
  • ADCC / ADCP where applicable
  • Target-cell depletion
  • Exposure-response relationship

Reference compounds or appropriate Fc variants can be incorporated when comparative pharmacological validation is required.

Frequently Asked Questions

When should I use an hFcRn humanized mouse?

An hFcRn model is most useful when FcRn-dependent IgG recycling may influence half-life, clearance, repeat-dose exposure, or dosing interval. This may apply to AOCs, antibody-siRNA conjugates, Fc-fusion formats, and Fc-engineered antibodies.

Does hFcRn humanization replace target humanization?

No. hFcRn humanization addresses Fc-dependent PK. If the targeting moiety recognizes only a human receptor or antigen, or if the oligonucleotide payload is specific for a human transcript, additional target, receptor, or transcript humanization may be required.

When is an hFcγR model useful?

An hFcγR model may be useful when Fc receptor interactions could influence target-cell depletion, immune-cell binding, cellular uptake, tissue sequestration, Fc-mediated activity, or immune activation.

Can FcRn/FcγR humanized mice be combined with humanized target models?

Yes. Combined configurations may be appropriate when a molecule requires human target binding, Fc-dependent exposure, Fc-mediated cellular interaction, and/or human-sequence-specific RNA modulation.

Discuss Your Humanized Fc Model Strategy

Share your therapeutic format, target, Fc design and study objectives with our team. We can help determine whether hFcRn, hFcγR, or a combined humanized configuration is appropriate for your in vivo PK/PD and pharmacological evaluation.

* For research use only. Not intended for any clinical use.
Quick Inquiry